"We are encouraged by this rPFS result, which compares favorably to small molecule radioligand therapy phase 1 and 2 studies at similar stages of development. This is a compelling signal of the potential efficacy of TLX591 in this heavily pre-treated population. "...but we can do better!
TLX591 (177Lu rosopatamab tetraxetan)... - Advanced Prostate...
TLX591 (177Lu rosopatamab tetraxetan) demonstrated promising radiographic progression-free survival (rPFS) in mCRPC
Written by
Maxone73
To view profiles and participate in discussions please or .
1 Reply
•
TLX591 is their own name for J591 monoclonal antibody radioligand. Yes, very effective for some (including me!) Also being used with Ac225 in clinical trial at Weill Cornell.
Not what you're looking for?
You may also like...
Pluvicto increases radiographic progression-free survival (rPFS) before chemo
metastatic and castration resistant (mCRPC)
(4) It was compared to following with one of the other...
Time to PSA Nadir is related to progression-free-survival
\\"Third Phase\\" (where the Time to PSA Nadir is greater than 17 months). In this \\"Third...
VISION trial results of Lu-177-PSMA-617
artis-announces-positive-result-phase-iii-study-radioligand-therapy-177lu-psma-617-patients-advanced
Oh guys, this one is good for mCRPC: Biologic Drug-Device Combination Immunotherapy Shows Promise for Patients with mCRPC
shows-promise-for-patients-with-metastatic-prostate-cancer/...
How Long Does the FDA’s Real-Time Oncology Review Program Take to Approve New Drug Applications?
ED injections and OS/rPFS
Just a spoonful of sugar helps the PCa medicine go down.
Definition of terms request
